Showing 5,101 - 5,120 results of 226,904 for search '(( a ((nn decrease) OR (a decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 1.63s Refine Results
  1. 5101
  2. 5102
  3. 5103
  4. 5104
  5. 5105
  6. 5106
  7. 5107
  8. 5108
  9. 5109
  10. 5110

    <b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b> by Ewan R. Pearson (157520)

    Published 2025
    “…<p dir="ltr">This post hoc analysis assessed sustainability of lowered HbA1c and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. …”
  11. 5111

    Correlations between volumetric decrease in rACC and average cortisol levels for patients (A) and controls (B) and correlations between volumetric decrease in rACC and the combined CTQ scales for physical and sexual abuse for patients (C) and controls (D). by Michael T. Treadway (371126)

    Published 2013
    “…<p>Correlations between volumetric decrease in rACC and average cortisol levels for patients (A) and controls (B) and correlations between volumetric decrease in rACC and the combined CTQ scales for physical and sexual abuse for patients (C) and controls (D).…”
  12. 5112

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  13. 5113
  14. 5114
  15. 5115
  16. 5116
  17. 5117

    Polymorphisms in <i>CYP1B1</i>, <i>CYP3A5</i>, <i>GSTT1</i>, and <i>SULT1A1</i> Are Associated with Early Age Acute Leukemia by Bruno Almeida Lopes (740876)

    Published 2015
    “…<i>CYP1B1</i> polymorphism was associated with a decreased risk of AML either for non-white or female children (additive model: OR = 0.24; 95% CI: 0.08–0.76, <i>p</i> < 0.01; additive model: aOR = 0.27; 95% CI: 0.08–0.89, <i>p</i> = 0.03, respectively). …”
  18. 5118

    Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study by Mutsumi Iijima (6743459)

    Published 2019
    “…<p><b>Background</b>: Gait disorders are common in Parkinson’s disease patients who respond poorly to dopaminergic treatment. Blockade of adenosine A<sub>2A</sub> receptors is expected to improve gait disorders. …”
  19. 5119

    Effects of Hypoxia Exposure on Hepatic Cytochrome P450 1A (CYP1A) Expression in Atlantic Croaker: Molecular Mechanisms of CYP1A Down-Regulation by Md. Saydur Rahman (151771)

    Published 2012
    “…Hypoxia exposure (dissolved oxygen, DO: 1.7 mg/L for 2 to 4 weeks) caused significant decreases in hepatic CYP1A mRNA and protein levels compared to CYP1A levels in fish held in normoxic conditions. …”
  20. 5120